Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company developing Gene Circuit-based cell and gene therapies, has appointed Bryan Baum to its Board of Directors. Baum, Co-Founder and Managing Partner of K5 Global, brings extensive entrepreneurial and investment experience with investments in major companies like SpaceX, OpenAI, and Uber.
As a serial entrepreneur, Baum has founded and successfully sold multiple companies, including Parrot (sold to Filevine), Blue Vision Labs (sold to Lyft), and Represent.com (sold to CustomInk). His expertise in scaling successful companies and strategic insights will support Senti Bio's development of Logic Gated cell therapies for cancer treatment.
Senti Biosciences (Nasdaq: SNTI), un'azienda biotecnologica in fase clinica che sviluppa terapie cellulari e geniche basate su circuiti genetici, ha nominato Bryan Baum nel suo Consiglio di Amministrazione. Baum, co-fondatore e managing partner di K5 Global, porta con sé una vasta esperienza imprenditoriale e di investimento, avendo partecipato a investimenti in importanti aziende come SpaceX, OpenAI e Uber.
Imprenditore seriale, Baum ha fondato e venduto con successo diverse società, tra cui Parrot (venduta a Filevine), Blue Vision Labs (venduta a Lyft) e Represent.com (venduta a CustomInk). La sua esperienza nella crescita di aziende di successo e le sue intuizioni strategiche sosterranno lo sviluppo da parte di Senti Bio di terapie cellulari con logica gated per il trattamento del cancro.
Senti Biosciences (Nasdaq: SNTI), una empresa biotecnológica en etapa clínica que desarrolla terapias celulares y génicas basadas en circuitos genéticos, ha nombrado a Bryan Baum en su Junta Directiva. Baum, cofundador y socio gerente de K5 Global, aporta una amplia experiencia empresarial e inversionista, habiendo invertido en compañías importantes como SpaceX, OpenAI y Uber.
Como emprendedor en serie, Baum ha fundado y vendido con éxito varias empresas, incluyendo Parrot (vendida a Filevine), Blue Vision Labs (vendida a Lyft) y Represent.com (vendida a CustomInk). Su experiencia en escalar empresas exitosas y sus conocimientos estratégicos apoyarán el desarrollo por parte de Senti Bio de terapias celulares con lógica gated para el tratamiento del cáncer.
Senti Biosciences (나스닥: SNTI)는 유전자 회로 기반 세포 및 유전자 치료제를 개발하는 임상 단계의 생명공학 회사로, Bryan Baum을 이사회 멤버로 임명했습니다. Baum은 K5 Global의 공동 창립자이자 매니징 파트너로서 SpaceX, OpenAI, Uber 등 주요 기업에 투자한 폭넓은 기업가 정신과 투자 경험을 보유하고 있습니다.
연쇄 창업가인 Baum은 Parrot(파일바인에 매각), Blue Vision Labs(Lyft에 매각), Represent.com(CustomInk에 매각) 등 여러 회사를 설립하고 성공적으로 매각한 경력이 있습니다. 성공적인 기업 확장 경험과 전략적 통찰력은 암 치료용 로직 게이트 세포 치료제 개발에 있어 Senti Bio를 지원할 것입니다.
Senti Biosciences (Nasdaq : SNTI), une société de biotechnologie en phase clinique développant des thérapies cellulaires et géniques basées sur des circuits génétiques, a nommé Bryan Baum au sein de son conseil d'administration. Baum, co-fondateur et associé directeur de K5 Global, apporte une vaste expérience entrepreneuriale et en investissement, ayant investi dans des entreprises majeures telles que SpaceX, OpenAI et Uber.
Entrepreneur en série, Baum a fondé et vendu avec succès plusieurs entreprises, notamment Parrot (vendue à Filevine), Blue Vision Labs (vendue à Lyft) et Represent.com (vendue à CustomInk). Son expertise dans le développement d'entreprises florissantes et ses perspectives stratégiques soutiendront le développement par Senti Bio de thérapies cellulaires à logique conditionnelle pour le traitement du cancer.
Senti Biosciences (Nasdaq: SNTI), ein biotechnologisches Unternehmen in der klinischen Phase, das zell- und gentherapeutische Ansätze auf Basis von Gen-Schaltkreisen entwickelt, hat Bryan Baum in seinen Vorstand berufen. Baum, Mitbegründer und geschäftsführender Partner von K5 Global, bringt umfassende unternehmerische und Investment-Erfahrungen mit, darunter Beteiligungen an bedeutenden Unternehmen wie SpaceX, OpenAI und Uber.
Als Serienunternehmer hat Baum mehrere Unternehmen gegründet und erfolgreich verkauft, darunter Parrot (verkauft an Filevine), Blue Vision Labs (verkauft an Lyft) und Represent.com (verkauft an CustomInk). Seine Expertise im Ausbau erfolgreicher Unternehmen und seine strategischen Erkenntnisse werden die Entwicklung von Logic Gated Zelltherapien zur Krebsbehandlung bei Senti Bio unterstützen.
- Addition of successful tech entrepreneur and investor with over 200 personal investments in major companies
- Board member brings expertise in scaling companies and strategic development
- New director has experience with AI and technology companies, relevant for Senti's gene circuit platform development
- None.
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors.
Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures.
Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive Officer, commented, “We are pleased to welcome Bryan to our Board of Directors. His keen insight and successful track record have equipped him with invaluable expertise on investing in and scaling successful companies that we believe will be a key asset to Senti as we continue to advance our programs. We look forward to leveraging his leadership and skillset to help propel Senti to fully realize the potential of our Gene Circuits.”
Mr. Baum added, “Senti’s engineering of Logic Gated cell therapies represents an exciting frontier with the potential to transform treatments for cancer indications not addressable by existing drugs. I am excited to work closely with the team to help execute on the development path forward and optimize value in the near and long term for all stakeholders.”
Mr. Baum also started 818 Tequila and previously founded and sold multiple companies including Parrot, a legal tech company using AI to accelerate workflows and depositions (sold to Filevine in 2025); Blue Vision Labs, a localization and mapping software company for self-driving cars (sold to Lyft in 2018); Operam, a data analytics and marketing insights company; and Represent.com, an e-commerce platform (sold to CustomInk in 2016). Mr. Baum has been an angel investor for over a decade and has personally made over 200 investments in companies such as Uber, Airbnb, Slack, Flexport, Carta, PillPack, and Sweetgreen.
Bryan was named a Technology Pioneer by the World Economic Forum, featured in Forbes 30 under 30, and is on the board of the Federal Drug Agents Foundation. Bryan studied Game Theory at Swarthmore College and Oxford University and was an adjunct professor at the University of Southern California.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Forward-Looking Statements
This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, expectations regarding Senti Bio’s progress future results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial start up, clinical studies, patient enrollment, and GMP manufacturing startup activities, (vii) Senti Bio’s dependence on third parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of the grant from CIRM, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
Who is Bryan Baum and why did Senti Bio (SNTI) appoint him to the Board?
What companies has Bryan Baum invested in before joining Senti Bio's board?
What is Senti Bio's (SNTI) main technology focus?
What companies has Bryan Baum founded and sold before joining Senti Bio?
What are Bryan Baum's academic and professional achievements?
